Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $272,087.52 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONSGet Rating) EVP Patrick R. O’neil sold 6,792 shares of the company’s stock in a transaction on Tuesday, April 12th. The stock was sold at an average price of $40.06, for a total value of $272,087.52. Following the transaction, the executive vice president now directly owns 34,536 shares in the company, valued at approximately $1,383,512.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Ionis Pharmaceuticals stock opened at $40.97 on Friday. Ionis Pharmaceuticals, Inc. has a 52 week low of $25.04 and a 52 week high of $44.10. The company has a current ratio of 9.75, a quick ratio of 9.65 and a debt-to-equity ratio of 1.62. The business’s 50-day simple moving average is $34.87 and its 200-day simple moving average is $32.66.

Ionis Pharmaceuticals (NASDAQ:IONSGet Rating) last released its quarterly earnings data on Thursday, February 24th. The company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $0.80 by $0.61. Ionis Pharmaceuticals had a negative return on equity of 4.37% and a negative net margin of 3.45%. The company had revenue of $440.00 million for the quarter, compared to analyst estimates of $284.08 million. During the same period in the prior year, the company posted ($2.44) EPS. The company’s revenue was up 51.7% compared to the same quarter last year. As a group, research analysts predict that Ionis Pharmaceuticals, Inc. will post -2.39 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. Mitchell & Pahl Private Wealth LLC acquired a new position in Ionis Pharmaceuticals during the 1st quarter worth $203,000. Gateway Investment Advisers LLC increased its position in shares of Ionis Pharmaceuticals by 16.5% in the 1st quarter. Gateway Investment Advisers LLC now owns 99,129 shares of the company’s stock valued at $3,672,000 after buying an additional 14,026 shares in the last quarter. Glassman Wealth Services increased its position in shares of Ionis Pharmaceuticals by 61.0% in the 1st quarter. Glassman Wealth Services now owns 681 shares of the company’s stock valued at $25,000 after buying an additional 258 shares in the last quarter. Bard Financial Services Inc. increased its position in shares of Ionis Pharmaceuticals by 138.5% in the 1st quarter. Bard Financial Services Inc. now owns 99,020 shares of the company’s stock valued at $3,668,000 after buying an additional 57,500 shares in the last quarter. Finally, Brookstone Capital Management increased its holdings in Ionis Pharmaceuticals by 60.4% during the 1st quarter. Brookstone Capital Management now owns 22,371 shares of the company’s stock worth $886,000 after purchasing an additional 8,424 shares in the last quarter. 83.97% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts recently weighed in on the company. StockNews.com assumed coverage on Ionis Pharmaceuticals in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Guggenheim began coverage on Ionis Pharmaceuticals in a research note on Tuesday, March 1st. They issued a “buy” rating and a $64.00 target price for the company. Citigroup began coverage on Ionis Pharmaceuticals in a research note on Monday, February 28th. They issued a “sell” rating and a $26.00 target price for the company. Bank of America lowered Ionis Pharmaceuticals from a “buy” rating to an “underperform” rating and lowered their price objective for the company from $40.00 to $30.00 in a research note on Tuesday, February 1st. Finally, SVB Leerink lowered their price objective on Ionis Pharmaceuticals from $29.00 to $26.00 and set a “market perform” rating for the company in a research note on Friday, April 1st. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $42.28.

About Ionis Pharmaceuticals (Get Rating)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.

See Also

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.